Feed EWTX
EW

Edgewise Therapeutics EWTX · NASDAQ

$39.99 +0.86% (+$0.34)

Market cap
$4.30B
Enterprise value
$4.23B
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/FCF
-
EV/EBITDA
-
ROIC
-48.5%
Gross margin
-
Net margin
-
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
0.28
Free float
76.1%

About the company

Edgewise Therapeutics, Inc. is a biotechnology company based in the United States that focuses on the development of therapeutic drugs for rare genetic diseases. The company specializes in innovative approaches in gene therapy and targets conditions such as Duchenne muscular dystrophy and other muscle disorders. Edgewise Therapeutics uses advanced scientific methods to develop drugs with the potential to significantly improve the quality of life for patients suffering from these serious and currently challenging-to-treat conditions.

Sector

Healthcare

Industry

Biotechnology

CEO

Kevin Koch

Employees

127

Headquarters

Boulder

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy